Kyle B. Brothers, MD, PhD and Esther E. Knapp, MD, MBE
Direct-to-consumer genetic testing requires that physicians share decision making with patients, not order unnecessary tests or interventions, and refer to genetic specialists when necessary.
AMA J Ethics. 2018;20(9):E812-818. doi:
10.1001/amajethics.2018.812.
Clara C. Hildebrandt, MD and Jonathan M. Marron, MD, MPH
Gene editing with CRISPR/Cas9 raises concerns about equitable access to therapies that could limit research participation by minority group members. These concerns can be addressed through public education, transparency, and stakeholder partnerships.
AMA J Ethics. 2018;20(9):E826-833. doi:
10.1001/amajethics.2018.826.
The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Defining typical appearance as a goal of health service provision is harmful and unnecessary for traits that are stigmatized but neither harmful nor distressing.
AMA J Ethics. 2021;23(7):E569-575. doi:
10.1001/amajethics.2021.569.
Dr Helen Stanton Chapple joins Ethics Talk to talk about teaching health professions students and trainees about acknowledging and realizing dying in a healthy way.
A bioethicist argues that children with Down syndrome should not be subjected to cosmetic surgery to change their appearance unless they are at the age and have the capacity to make the decision for themselves.